Skip to main content

Monoclonal Antibodies against 2019-New Coronavirus

Objective

"Lessons learned from, and intervention efforts against SARS coronavirus (CoV), MERS-CoV and other emerging viruses provide invaluable information to accelerate the coordinated response against 2019 novel (2019 -n)CoV and the rapid development and manufacture of new diagnostic, prophylactic and therapeutic intervention strategies. A -promising approach to both patient management of emerging viral infections and to better preparedness and response to emerging epidemics is the use of monoclonal antibodies. MANCO aims at contributing to the rapid international response against 2019-nCoV, through preclinical and clinical evaluation of monoclonal antibodies against 2019-nCoV. MANCO will build on and leverage outstanding results from ongoing IMI-funded project #115760 ZAPI, including recently-discovered broadly cross-reactive H2L2 monoclonal antibodies against betacoronaviruses and an established pipeline for rapid identification of specific H2L2 monoclonal antibodies against 2019-nCoV; antibodies that will be selected to proceed to GMP manufacturing in high-yield CHO cell-lines. This project furthermore builds on ZAPI consortium’s experience and expertise for the development and establishment of relevant animal models, to ensure preclinical efficacy and safety, including absence of antibody-dependent enhancement, an issue seen to occur in some immunization studies against feline and SARS CoVs. Based on the generated preclinical data, MANCO will advance one lead (prophylactic and/or therapeutic) monoclonal antibody into a Phase I clinical trial that can be completed within two years of the start of the project, by leveraging clinical expertise, infrastructure and network currently in place for ongoing CEPI-funded projects on candidate vaccines against MERS-CoV (#INID1801) and Rift Valley Fever virus (#INLA1901), and H2020-funded projects on improved vaccines targeting the elderly (ISOLDA #848166) and on universal influenza vaccines, including in LMICs (ENDFLU #874650)."

Field of science

  • /medical and health sciences/health sciences/infectious disease/RNA virus/coronavirus

Call for proposal

H2020-SC1-PHE-CORONAVIRUS-2020
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Address
Dr Molewaterplein 40
3015 GD Rotterdam
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 351 250

Participants (7)

HARBOUR ANTIBODIES BV
Netherlands
EU contribution
€ 100 000
Address
Stationsplein 45, A4.004
3013 AK Rotterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITEIT UTRECHT
Netherlands
EU contribution
€ 219 627,50
Address
Heidelberglaan 8
3584 CS Utrecht
Activity type
Higher or Secondary Education Establishments
STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER
Germany
EU contribution
€ 130 000
Address
Bunteweg 2
30559 Hannover
Activity type
Higher or Secondary Education Establishments
AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS
Spain
EU contribution
€ 125 001,25
Address
Calle Serrano 117
28006 Madrid
Activity type
Research Organisations
ASSOCIATION INTERNATIONALE DE STANDARDISATION BIOLOGIQUE POUR L'EUROPE (IABS-EU)
France
EU contribution
€ 131 625
Address
Boulevartd Vivier Merle 10-12 World Trade Center Tour Oxygene
69393 Lyon
Activity type
Other
CR2O BV
Netherlands
EU contribution
€ 1 803 827,50
Address
Bisonspoor 3002, C701
3605 LT Maarssen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
FINOVATIS
France
EU contribution
€ 173 250
Address
Cours Lafayette 68
69003 Lyon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)